Dan Adelman, M.D.

Previously Jasper’s acting CMO, Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals. Previously Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharmacyclics, and as a Clinical Scientist at Genentech where he was involved in the early development of omalizumab and bevacizumab. Dr. Adelman has also led the development of other therapies for celiac disease and food allergy. Dr. Adelman began his career as an Assistant Professor of Clinical Medicine in the Division of Allergy and Immunology at the University of California, San Francisco, School of Medicine, where he was also Director of Clinical Allergy and Immunology. He is also currently an Adjunct Professor of Medicine at UCSF, where he has taught and practiced at for more than 34 years, remaining on the faculty upon entering industry. He has also served on the editorial boards of the Journal of Clinical Immunology and Clinical Immunology, and as a clinical advisor to multiple biopharmaceutical companies. Dr. Adelman holds a bachelor’s degree in biology from the University of California, Berkeley, and earned his M.D. from the University of California, Davis.